Status | Study |
Recruiting |
Study Name: A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Condition: Persistent or Recurrent Cutaneous T-Cell Lymphoma Date: 2013-03-28 Interventions: Drug: E7777 administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive |
Active, not recruiting |
Study Name: Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) Condition: Cutaneous T Cell Lymphoma Date: 2012-07-15 Interventions: Drug: Topical resiquimod 0.06% |
Terminated |
Study Name: Everolimus in Treating Cutaneous T-cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2012-04-02 Interventions: Drug: Everolimus The study drug everolimus will be self-ad |
Completed |
Study Name: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Condition: Cutaneous T Cell Lymphoma Date: 2010-05-25 Interventions: Drug: Lenalidomide Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated |
Completed |
Study Name: Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Condition: Refractory Cutaneous T-cell Lymphoma Date: 2009-11-03 Interventions: Drug: bexarotene 150 mg/m2/day |
Withdrawn |
Study Name: Trial of Curcumin in Cutaneous T-cell Lymphoma Patients Condition: Cutaneous T-cell Lymphoma Date: 2009-08-27 Interventions: Drug: Curcumin (Turmeric) |
Terminated |
Study Name: Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2009-02-24 Interventions: Procedure: skin biopsy Lidocaine 1% c Epinephrine for local anesthesia |
Completed |
Study Name: Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study Condition: Cutaneous T-Cell Lymphoma Date: 2008-10-22 Interventions: Drug: Tazarotene Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase |
Completed |
Study Name: A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2008-08-29 Interventions: Drug: Enzastaurin 1125 mg loading dose then 500 mg, oral, daily, until disease progression |
Completed |
Study Name: Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma Condition: Cutaneous T-cell Lymphoma Date: 2007-11-05 Interventions: Drug: Pralatrexate Injection |